Locations:
SearchCurrent rate of increase isn’t sustainable
Treatment cost is a major determinant of value in a value-based healthcare system. The rapidly escalating costs of new cancer treatments threaten the sustainability of value-based cancer care.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
There’s no easy fix, says Taussig Cancer Institute Chairman Brian J. Bolwell, MD, FACP, of Cleveland Clinic Cancer Center, but a start is greater collaboration among those with most at stake: healthcare providers, payers and the pharmaceutical industry.
Click here to view more cancer related videos.
Photo Credit ©Russell Lee
PLEASE EMBED VIDEO HERE (video 6 in the drop box link)
Advertisement
Advertisement
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Global R&D efforts expanding first-line and relapse therapy options for patients
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
A case study on the value of access to novel therapies through clinical trials
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456
Key learnings from DESTINY trials
Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients